Lung Cancer Triplet Therapy Trial Results Reported
A phase II study showed clinical activity for a combination treatment in patients with EGFR-mutant lung cancer.
Updated on Oct. 6, 2026 in Cancer
A phase II clinical trial involving 61 patients evaluated a combination of amivantamab, lazertinib, and bevacizumab for advanced non-small cell lung cancer. Results reported in May 2024 showed a 33% objective response rate at 12 weeks for patients who had previously progressed on third-generation EGFR tyrosine kinase inhibitors.
Why it matters
The study explored a triplet biologic combination targeting the EGFR, MET, and angiogenic pathways to address patients whose cancer had advanced despite prior targeted therapies. This approach aims to overcome resistance mechanisms in patients with EGFR-mutant non-small cell lung cancer.
The study reported a 10.9-month median progression-free survival and a 19.9-month median overall survival. Grade 3-4 treatment-related adverse events occurred in 43% of the 61 enrolled patients.
The players
EGFR-mutant non-small cell lung cancer
This is a specific form of lung cancer driven by epidermal growth factor receptor gene mutations.
The details
Researchers tested the triplet therapy across 17 study sites to target multiple cancer progression pathways simultaneously. While the treatment showed a 39% best overall response rate, 17% of patients experienced treatment-related venous thromboembolism.
Timeline
Trial enrollment began in March 2023.
Trial enrollment ended in May 2024.
Health Landscape
This research builds upon the established use of third-generation EGFR tyrosine kinase inhibitors as a baseline treatment for this cancer type. By testing a triplet biologic combination, the study marks an effort to move beyond current resistance patterns observed in clinical practice.
The findings highlight the safety profile of this intensive combination, including a 20% rate of serious treatment-related adverse events. Patients should discuss potential side effects, such as the risk of venous thromboembolism, with their oncologists when considering experimental protocols.
The takeaway
This phase II trial demonstrates that targeting multiple biological pathways can produce clinical responses in patients with limited options. Managing the higher incidence of adverse events remains a critical factor for future clinical applications of such triplet therapies.
Further reading
For more information on current treatment paradigms, visit the Cancer section.
Source note: This article includes information reported by MedPage Today.
